Lyell Immunopharma (NASDAQ:LYEL) President and CEO Lynn Seely outlined the company’s clinical development priorities, regulatory strategy and manufacturing plans during a Stifel investor session moderated by Stephen Willey, senior biotech analyst at Stifel.
Seely described Lyell as a cell therapy company focused on next-generation treatments for hematologic malignancies and solid tumors. She highlighted two lead clinical programs: ronde-cel, a CD19/CD20 CAR T-cell therapy being developed in large B-cell lymphoma, and LYL273, a GC-C-targeting CAR T-cell therapy for metastatic colorectal cancer.
